ArticleScientific reports2026
LINC01857 promotes clear cell renal cell carcinoma progression by scaffolding DNMT1 to suppress WIF1 expression.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The long intergenic non-coding RNA LINC01857 has been implicated in various human malignancies; however, its specific role in clear cell renal cell carcinoma (ccRCC) remains unclear. In this study, we report that LINC01857 is markedly upregulated in ccRCC tissues and cell lines. Functionally, LINC01857 knockdown suppressed the proliferation, migration, and invasion of ccRCC cells, whereas its overexpression promoted these malignant phenotypes. Mechanistically, LINC01857 recruits the DNA methyltransferase DNMT1 to the WIF1 promoter, leading to promoter hypermethylation and transcriptional repression of WIF1. This epigenetic repression of WIF1, in turn, activates the Wnt/β-catenin pathway, which contributes to the aggressive behaviors of ccRCC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.